Rilmenidine Hydrogen Phosphate API

Minakem Beuvry-la-Forêt was the first site acquired by Minafin (formerly SEAC) in 2005.
The site has extensive expertise in R&D and analytical development and has been manufacturing Active Pharmaceutical Ingredients (APIs) for over 20 years.

In 2023, a significant investment of 35 million EUR was made to enhance its competitiveness in API manufacturing and to improve its HSE ranking through the implementation of a modern COV (Volatile Organic Components) reduction system.

The site specializes in low-temperature chemistry (e.g., Suzuki coupling, lithiation), cyanuration, bromination, hydrogenation, and more. Additionally, it excels in solid engineering design, enabling the efficient management of polymorphism and particle size distribution (PSD).

Strategically located in the heart of Europe, between Lille, Paris, and Brussels, the site exports 90% of its production globally.

Minakem Beuvry-la-Forêt collaborates daily with Minakem’s other European facilities, leveraging their complementary expertises in solid engineering, analytics, global regulatory affairs, and other capabilities to enhance competitiveness.

Minakem brings over 40 years of experience in developing, scaling up, registering Drug Master Files (DMFs), and manufacturing complex Active Pharmaceutical Ingredients (APIs), including chiral small molecules, steroids, and highly potent APIs (HPAPIs)—primarily used in oncology treatments.

As supply chain performance becomes increasingly critical to customers’ success, Minakem focuses on delivering:

• Safe products for patients,
• High On-Time-In-Full (OTIF) performance,
• Robust quality support, and
• Innovative solutions to address customers’ unexpected market demands.